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Abstract 
The prevalence of neurodegenerative diseases, such as Alzheimer’s disease (AD), has been 
progressively increasing each year, in which AD is now the sixth leading cause of death in the 
United States (Alzheimer's Association, 2017). The effects of neurodegenerative diseases present 
a massive challenge for society and health care systems globally, and as a result, examining the 
pathogenesis of these diseases have been a common aim throughout past literature. Nonetheless, 
the molecular mechanisms that underlie neurodegenerative diseases are still fundamentally 
undetermined, yet studying to understand the pathogeneses can provide extensive information for 
the development of curative treatments. In particular, fully understanding the protein eukaryotic 
initiation factor (eIF2) can provide insight into the molecular pathways that may give rise to 
neurodegenerative disorders. Through the critical review of two research articles, this paper 
investigates the association between eIF2 and neurodegenerative diseases, specifically AD and 
prion disease, in efforts to understand the molecular mechanisms that underlie these disorders.  
Through critically analyzing Ma et al. (2013) and Moreno et al. (2012), it is evident that the eIF2 
pathway plays a vital role in the pathogenesis of these neurodegenerative disorders. 
Incorporating the findings from both studies together, it can be proposed that with further 
research, the proteins within the eIF2 process can possibly be used as targets for novel therapies 
to treat these disorders. These two articles provide vast future directions for further research to 
extend upon, in order to reveal more regarding the significance of eIF2 signalling in mitigating 
synaptic failure, neuronal loss, behavioural dysfunctions, and ultimately battle the massive global 
challenge that is presented by neurodegenerative diseases.   
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A Critical Review on the Association between eIF2 and Neurodegenerative Diseases 
The prevalence of neurodegenerative diseases, such as Alzheimer’s disease (AD), has 
been progressively increasing each year, in which AD is now the sixth leading cause of death in 
the United States (Alzheimer's Association, 2017). The effects of neurodegenerative diseases 
present a massive challenge for society and health care systems globally, and as a result, 
examining the pathogenesis of these diseases have been a common aim throughout past 
literature. Nonetheless, the molecular mechanisms that underlie neurodegenerative diseases are 
still fundamentally undetermined, yet studying to understand the pathogeneses can provide 
extensive information for the development of curative treatments. Neurodegenerative diseases 
such as AD, Parkinson’s disease, Huntington’s disease, and prion diseases have different clinical, 
pathological and biochemical conditions, however they all share notable similarities that involve 
the accumulation of misfolded proteins, as well as mechanisms that result in neuronal loss 
(Halliday & Mallucci, 2013). In particular, fully understanding the unfolded protein response 
(UPR) can provide insight into the molecular pathways that may give rise to these disorders. 
Specifically, eukaryotic initiation factor (eIF2) has been widely emphasized in previous research 
to having a vital role in this process, along with its connection to neurodegenerative diseases. 
Through the critical review of two research articles, this paper aims to investigate the association 
between eIF2 and neurodegenerative diseases, specifically AD and prion disease, in efforts to 
understand the molecular mechanisms that underlie these disorders.  
 Neurodegenerative diseases are characterized by the gradual death of nerve cell 
populations, along with the accumulation of protein aggregates (Barnham, Masters, & Bush, 
2004). In particular, AD is the most common cause of dementia, which is characterized by issues 
with memory, thinking and behaviour (Holtzman, Morris, Goate, 2011). Throughout past 
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literature, there have been numerous approaches to determining the molecular pathways involved 
in AD. For instance, previous research has focused on the accumulation of amyloid plaques in 
the brain, which are derived from amyloid-β (Aβ) peptides, and how these plaques are related to 
the development of AD (Golde, Eckman, & Younkin, 2000; Hardy & Selkoe, 2002). Likewise, 
Holtzman and colleagues (2011) found that the pathogenesis of AD also includes the 
development of neurofibrillary tangles (NFTs) of the protein Tau, along with the loss of synapses 
and neuronal cell death. Cell death can be attributed to prolonged activation of the UPR due to 
increased endoplasmic reticulum stress (Lindholm, Wootz, & Korhonen, 2006). Therefore, 
examining essential proteins involved in the UPR pathway such as eIF2, along with their 
contribution to synaptic dysfunction and memory impairments, can provide greater knowledge of 
the development of AD.  
 In similar ways, prion disease, another neurodegenerative disorder, has been heavily 
explored in the disciplines of neuropathology and biochemistry. Prion diseases are caused by the 
buildup of the misfolded forms of the prion protein (PrP), which leads to neurodegeneration and 
neurological defects (Eikelenboom et al., 2002). The pathogenesis of prion diseases involves the 
conversion of normal, cellular prion protein (PrPC) to abnormal, misfolded, protease-resistant 
prion protein (PrPSc) that accumulate into aggregates in the brain (Prusiner, 1991). As a result, 
prion diseases cause increased levels of PrPSc, resulting in prolonged activation of the UPR, 
which consequently reduces the levels of synaptic proteins (Lindholm et al., 2006; Prusiner, 
1991). The decline of synaptic proteins could be due to increased protein degradation or 
decreased protein synthesis. However, prion infections have been discovered to hinder the 
ubiquitin proteasome system, thus reducing protein degradation, suggesting that the reduction of 
protein levels are from decreased protein synthesis (Kristiansen et al., 2007). Therefore, 
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investigating proteins such as eIF2, which are involved in molecular mechanisms that lead to 
decreased protein synthesis, can offer greater understanding of prion diseases, in order to 
ultimately develop treatments targeting prion infections.	
 The protein eIF2 is essential in regulating protein synthesis through its contribution in the 
UPR (Cao & Kaufman, 2012). To be specific, whether or not the α subunit of eIF2 is 
phosphorylated by kinases or dephosphorylated by phosphatases have distinct and extensive 
effects on translational control in cells. Phosphorylated eIF2α (eIF2α-P) causes downstream cell 
signalling pathways that generally inhibit protein synthesis. Since neurodegenerative diseases, 
such as AD and prion disease, are characterized by neuronal cell death which is related to 
prolonged activation of UPR, exploring the relationship between eIF2α-P and the development 
of these neurodegenerative diseases is vital. The following two critical reviews attempt to 
demonstrate that eIF2α-P certainly plays a vital role in the pathogenesis of AD and prion disease. 
In turn, these two articles provide a basis where future investigations can extend upon, to further 
explore the association between eIF2α-P and neurodegenerative diseases, in order to ultimately 
discover potential therapeutic targets for treatments. 
 In a study conducted by Ma and colleagues (2013), their main objective was to explore 
whether or not inhibiting eIF2α kinases could improve synaptic plasticity and spatial memory in 
AD model mice. Specifically, they hypothesized that through genetically removing eIF2α 
kinases PERK and GCN2, levels of eIF2α-P will reduce, and as a result prevent AD-associated 
deficits in synaptic plasticity and memory. In their investigation, there were three primary goals 
addressed: PERK removal prevented Aβ-mediated defects, PERK deletion relieved abnormalities 
in AD mice, and the elimination of GCN2 alleviated AD-associated deficits.  
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Ma et al. (2013) first wanted to verify the differing levels of eIF2α-P in AD and wildtype 
(WT) mice, as well as examine the Aβ-linked effects of removing PERK. In order to investigate 
the role of eIF2α, they analyzed eIF2α-P levels in various brain areas of AD model mice. AD 
mice were transgenic, characterized by the overexpression of amyloid precursor protein (APP). 
Through western blots targeting eIF2α-P, they found increased eIF2α-P levels in the 
hippocampus and prefrontal cortex (PFC), but not in the cerebellum. Therefore, they confirmed 
that AD mice contained abnormally high concentrations of eIF2α-P. In addition, they explored 
whether Aβ-linked impairments in synaptic plasticity and memory could be improved by 
deleting PERK. Using WT mice that had a floxed PERK gene and Cre recombinase, they were 
able to knockout PERK in excitatory hippocampal neurons. They found that in WT mice, LTP-
inducing high-frequency stimulation (HFS) resulted in dephosphorylation of eIF2α, and thus 
increases in protein synthesis. However, in the presence of Aβ, LTP was inhibited in WT mice. 
In mice that had PERK removed, Aβ had no effect on LTP or hippocampal synaptic plasticity 
since it demonstrated similar LTP activity as WT mice. Therefore, by removing PERK, they 
found that Aβ-induced deficits in hippocampal synaptic plasticity were reduced. 
Ma and associates (2013) then explored the effects of decreasing eIF2α-P levels by 
genetically removing kinases (e.g., PERK) on protein synthesis, memory and synaptic plasticity. 
This time, they created AD transgenic mice that had floxed PERK genes and Cre recombinase, to 
knockout PERK. They analyzed the effects of PERK deletion on protein synthesis in 
hippocampal slices. In AD mice, they found reduced translation mediated by eIF2α-P, whereas 
in AD mice with PERK deleted, the reduction of protein synthesis was prevented. Hence, they 
discovered that PERK deletion stabilizes the effects on protein synthesis mediated by eIF2α 
phosphorylation. Furthermore, the researchers investigated how the removal of PERK would 
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impact spatial learning and memory. They tested the mice on three separate behavioural tasks: 
Morris water maze, object location, and Y water maze. AD mice demonstrated compromised 
learning and memory abilities by exhibiting decreased escape latency, greater target quadrant 
occupation, along with increased platform crossings. Conversely, AD mice that had PERK 
deleted did not display these spatial memory impairments. Additionally, they explored whether 
removing PERK could improve the synaptic plasticity defects. They measured synaptic plasticity 
through examining LTP; in AD mice, LTP was significantly reduced, while the deletion of 
PERK resulted in normal LTP. Therefore, removing PERK in AD mice restored LTP and 
alleviated synaptic plasticity deficits. 
Moreover, Ma and associates’ (2013) last primary goal was to study the effects on 
memory and synaptic plasticity through the deletion of GCN2, another eIF2α kinase. In similar 
ways, they found analogous results to the findings from deleting PERK, since the removal of 
GCN2 also reduced LTP failure and spatial memory deficits. Integrating all the findings from 
this article, it is clear that eIF2α-P plays a vital role in AD, since the suppression of eIF2α 
kinases resulted in counteractive AD-associated effects on protein synthesis, memory, and 
synaptic plasticity. Investigating the molecular mechanisms that are responsible for AD-related 
synaptic failure and memory impairments could offer innovative targets for AD treatments; for 
instance, future research on potential therapies that target specifically PERK and GCN2 have 
potential in relieving AD symptoms. 
 In another study, Moreno and colleagues (2012) explored the association between eIF2α-
P and neurodegeneration from prion disease. The general aim of the investigation was to 
demonstrate that translational repression of global protein synthesis was mediated by eIF2α-P, 
and plays a role in prion neurodegeneration. They expected that synaptic failure and neuronal 
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loss found in prion-infected mice were attributed to the constant inhibition of translation that was 
mediated by increased levels of eIF2α-P. Therefore, they also predicted that promoting 
translation by reducing eIF2α-P levels could be neuroprotective and reduce neuronal death. In 
this study, they attempted to address six primary goals. In order to test the relationship between 
eIF2α-P and prion disease, they used transgenic mice that expressed PrP levels three times 
greater than WT levels, and infected them with prion disease.  
Moreno et al. (2012) first determined the molecular mechanisms involved with the 
development of prion disease. Through numerous western blots, they found that throughout the 
progression of the disease, PrPSc levels increased gradually, while there were significant 
reductions in synapse proteins, synapse numbers, synaptic transmission, and burrowing 
behaviour at 9 weeks post infection (w.p.i.) in prion-infected mice. Consequently, they then 
explored the cause of this reduction in protein synthesis observed at 9 w.p.i., and discovered that 
levels of PERK-P and eIF2α-P increased at 9 w.p.i. Since PERK-P phosphorylates eIF2α	and 
eIF2α-P prevents the initiation of translation, they concluded that eIF2α-P mediates the 
significant reduction of protein synthesis found at 9 w.p.i. 
 In addition, analyzing polysomal fractions and northern blots, Moreno et al. (2012) 
investigated the precise effects of increasing eIF2α-P levels at 9 w.p.i. They found that when 
eIF2α-P levels grew, abrupt decreases in protein synthesis were observed through substantial 
reduction in global translation rates. Moreover, they then used different transgenic mice that 
expressed varying levels of PrP (i.e., 1x WT, 3x WT, 6x WT) and analyzed the relationship 
between eIF2α-P and the onset of neurodegeneration. They discovered parallel findings in all 
three strains of mice, where PrPSc levels increased, then a rise in levels of eIF2α-P were detected, 
followed by reductions in synapse numbers and synaptic protein levels. 
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 Furthermore, Moreno and associates (2012) explored the effects of whether reducing 
eIF2α-P levels could lead to neuroprotective effects. They used two lentiviral-mediated methods 
that targeted the hippocampus of prion-infected mice. They aimed to overexpress GADD34, an 
eIF2α-P phosphatase that reduced eIF2α-P levels directly, as well as perform targeted RNA 
interference of PrP to abolish UPR activation and prevent phosphorylation of eIF2α. Both the 
overexpression of GADD34 and PrP knockdown caused reductions in eIF2α-P levels, preventing 
the translational suppression, thereby restoring global translation rates in prion-infected mice. 
Additionally, synaptic protein and transmission levels were similar to WT levels, along with 
increased burrowing behaviour and an enhanced survival rate. Therefore, they discovered that 
decreasing eIF2α-P levels resulted in neuroprotective properties. In opposition, they examined 
whether increased levels of eIF2α-P would exacerbate prion neurotoxicity through injections of 
salubrinal, an inhibitor of eIF2α-P dephosphorylation. They found expected results, where 
salubrinal increased eIF2α-P levels, reduced global translation rates, decreased synaptic protein 
levels, and ultimately accelerated death rate. 
 There are wide implications that can be drawn from all the findings presented in the study 
by Moreno et al. (2012). Linking all the results together, it is evident that eIF2α-P causes 
repression of translation, and in turn, is associated with the onset of prion neurodegeneration. 
This article definitely provides a basis for future research to further investigate the mechanisms 
underlying prion disease, to ultimately explore novel therapies that target possibly eIF2α-P, in 
order to treat neurodegenerative disorders that involve misfolded proteins. 
 To critically evaluate the article by Ma and colleagues (2013), there are numerous aspects 
that strengthened their study, in which their findings altogether support the conclusions as well 
as address the original goal. Nonetheless, there are several limitations, though importantly, this 
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study provides future directions for research to improve the weaknesses of this investigation. 
One strength of their study is that their results clearly demonstrate that the removal of PERK or 
GCN2 indeed affects pathways in AD mice, and in turn influences protein synthesis, synaptic 
plasticity and memory. Their experiments followed a coherent order; for example, they 
confirmed that deleting PERK decreased PERK expression and eIF2α-P levels, and as a result, 
the reduction of protein synthesis mediated by eIF2α-P was prevented. One thing to appreciate is 
that they definitely provided substantial evidence for preventing AD-related effects by removing 
an eIF2α kinase. However, it cannot be concluded with certainty that the deletion of an eIF2α 
kinase was the sole factor that caused AD-associated synaptic plasticity and memory 
impairments to be alleviated. For instance, they focused on the effects of removing one specific 
eIF2α kinase PERK, and found improvements to spatial memory performance in AD mice. In 
contrast, a study by Zhu, Henninger, McGrath and Cavener (2016) found that PERK may indeed 
have a role in memory formation. Therefore, these two competing schools of thought suggest 
that PERK/eIF2α-P signalling is actually very complex, and is possibly involved in many 
mechanisms that all work together, to ultimately give rise to diverse cellular activities.  
Another limitation of the study by Ma et al. (2013) is that they only explored the effects 
in the hippocampus, however AD has been shown to affect numerous other regions, such as 
amygdala, cerebellum, and PFC (Holtzman et al., 2011). Ma and associates (2013) also 
confirmed increased levels of eIF2α-P within the PFC, in addition to the hippocampus of AD 
mice. Thus, a crucial question of whether removing eIF2α kinases would have similar effects in 
the PFC was not addressed. Similarly, they only investigated Aβ-induced deficits, yet AD is also 
characterized by NFTs of the Tau protein (Holtzman et al., 2011). Interestingly, Ohno (2014) 
found that the PERK pathway contributes to the hyper-phosphorylation of Tau, producing NFTs. 
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Therefore, this introduces a possibility in which removing PERK not only improves Aβ-induced 
deficits, but may also prevent NFT-related impairments. This brings into question the actual 
molecular mechanism that governs the alleviation of AD-related defects from deleting PERK. 
Lastly, they did not analyze the effects of eIF2α phosphatases, as they may also provide relief to 
AD-related deficits. Nonetheless, the study by Ma and colleagues (2013) overall has vital 
implications scientifically and clinically, in addition to serving as a groundwork experiment for 
future research to build upon. 
The experiment conducted by Moreno and associates (2012) also includes numerous 
strengths, in which their findings provide extensive support for how eIF2α-P mediates 
translational inhibition, and how it is linked to prion neurodegeneration. It is evident that the 
findings address the goals of the study because through manipulating the levels of eIF2α-P in 
prion-infected mice, signs of neurodegeneration were seen. The procedure that the researchers 
used to explore translational control by eIF2α-P and neuronal death can be appreciated, since 
they first confirmed that at 9 w.p.i., significant reductions in synapse numbers and protein levels 
were found. After, they determined that interestingly at 9 w.p.i., eIF2α-P levels increased, which 
caused the reduction in synaptic protein levels since eIF2α-P regulates inhibition of protein 
synthesis. They then focused and manipulated eIF2α-P levels at 9 w.p.i. to observe its 
association with neurodegeneration. Thus, this study followed a logical process that effective in 
analyzing the role of eIF2α-P. However, a limitation is that they solely focused on 9 w.p.i., yet at 
7 w.p.i. was when they first observed significant reductions in synapse numbers. Hence, the 
paper failed to address the question of what happened in between 6 w.p.i. to 9 w.p.i, that may 
have caused reductions in synapse numbers at 7 and 9 w.p.i. The study intended to analyze the 
molecular mechanisms which underlie prion neurodegeneration, but falls a little short as it left 
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several essential questions unanswered, specifically in regards to the progression leading up to 
synaptic changes in prion-infected mice. Furthermore, another critique of the paper is that the 
experiment did not take into account other factors that may influence the eIF2α pathway. As 
suggested in previous studies, eIF2α signalling is extremely intricate, and can have numerous 
influences that affect this pathway (Wek, Jiang, & Anthony, 2006; Zhu et al., 2016). Future 
studies should explore the effects of changing eIF2α-P levels by altering the expression of eIF2α 
kinases or phosphatases, and how that may impact prion disease. Despite the limitations to the 
investigation conducted by Moreno et al. (2012), the findings clearly demonstrate the role of 
eIF2α in repressing translation, and how this mechanism is linked with prion neurodegeneration. 
In conclusion, the critical analyses of the investigations by Ma et al. (2013) and Moreno 
et al. (2012) provide extensive evidence for greater understanding of the mechanisms that are 
responsible for AD and prion diseases. It is evident that the eIF2α pathway plays a vital role in 
the pathogenesis of these neurodegenerative disorders. Incorporating the findings from both 
studies together, it can be proposed that with further research, the proteins within the eIF2α 
process can possibly be used as targets for novel therapies to treat these disorders. These two 
investigations tested mice models, however after additional research, treatments that target this 
mechanism have potential to be implicated in clinical settings. Additionally, examining the link 
between other neurodegenerative disorders and the eIF2α pathway could be valuable, to 
ultimately discover more effective therapies. Nonetheless, these two papers provide vast future 
directions for further research to extend upon, in order to reveal more regarding the significance 
of eIF2α signalling in mitigating synaptic failure, neuronal loss, behavioural dysfunctions, and 
ultimately battle the massive global challenge that is presented by neurodegenerative diseases.   
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